Sign up to save your podcasts
Or
Share S09 E01: Lundbeck’s Charl van Zyl on a new era in neurology
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S09 E01: Lundbeck’s Charl van Zyl on a new era in neurology
The EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are joined by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions.
Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck’s plans for the future, the role of digital health technology and much more.
A little more on EMJ GOLD’s guest...
Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets.
Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.
View all episodes
By EMJThe EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are joined by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions.
Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck’s plans for the future, the role of digital health technology and much more.
A little more on EMJ GOLD’s guest...
Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets.
Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark.